Chemotherapeutic potential of betanin/capecitabine combination targeting colon cancer: experimental and bioinformatic studies exploring NFκB and cyclin D1 interplay

• Egile Nagusiak: Rehab Ahmed (Egilea), Sawsan A. Zaitone (Egilea), Asmaa K. K. Abdelmaogood (Egilea), Huda M. Atef (Egilea), Mona F. M. Soliman (Egilea), Alaa M. Badawy (Egilea), Howaida S. Ali (Egilea), AbdelNaser Zaid (Egilea), Hatem I. Mokhtar (Egilea), Lamiaa M. Elabbasy (Egilea), Emad Kandil (Egilea), Asmaa Mokhtar Yosef (Egilea), Rama I. Mahran (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Betanin (C₂₄H₂₆N₂O₁₃) is safe to use as food additives approved by the FDA with anti-inflammatory and anticancer effects in many types of cancer cell lines. The current experiment was designed to test the chemotherapeutic effect of the combination of betanin with the standard chemother...